Researchers compared sacituzumab tirumotecan, a TROP2-directed antibody drug conjugate, with platinum-based chemotherapy.
Immunotherapy in Non-Small Cell Lung Cancer
Advertisement
Other analyses suggest that lack of ctDNA clearance with neoadjuvant therapy or with MRD postsurgery leads to worse outcomes.
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
Dr. Archambault discusses the safety and effectiveness of cemiplimab plus chemotherapy for first-line treatment of aNSCLC.
Mariano Provencio, MD, PhD, presented the results of CheckMate 77T as a late-breaking abstract at ASCO 2025.
Patrick M. Forde, MD, presented the late-breaking abstract during an oral abstract session at the 2025 ASCO Annual Meeting.
Researchers tested Dato-DXd for safety and tolerability in patients with advanced NSCLC.
Ivonescimab plus chemotherapy “demonstrated a statistically significant and clinically meaningful improvement” in PFS.
Study Highlights Relationship Between Lipid Metabolism, NK Cells in the NSCLC Tumor Microenvironment
Study investigators suggested there may be a “promising therapeutic strategy for advancing NK cell-based immunotherapy."
The study explored the effect of immune checkpoint inhibition on real-world patients with NSCLC versus trial patients.
Solange Peters, MD, PhD, presented results from the trial evaluating tiragolumab plus atezolizumab.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.